New cocktail of drugs shows early promise against tough bile duct cancer
NCT ID NCT05348811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of three drugs—chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy—in 25 people with advanced bile duct cancer that could not be removed surgically. The goal was to see if the combination could shrink tumors and control the disease. Early results suggest the approach may be effective, but larger studies are needed to confirm safety and long-term benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HAIC (chemotherapy infused into the liver artery) plus donafenib (a targeted drug) and sintilimab (an immunotherapy drug)
- What this could lead to
- If this works, it could offer a new first-line treatment option for people with advanced bile duct cancer that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase study with only 25 participants. The combination may cause serious side effects, and it is not yet known if it improves survival compared to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?